BUDGET IMPACT ANALYSIS OF ALEMTUZUMAB IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN HEALTHCARE SOCIAL SECURITY (ESSALUD) IN PERU

被引：0
|
作者：
Moreno, M. [1 ]
Arce, J. [1 ]
Cruz, A. [2 ]
Carpio Farro, R. [3 ]
机构：
[1] Sanofi Aventis Colombia, Bogota, Cun, Colombia
[2] Hosp Alberto Sabogal, Magdalena Del Mar, Peru
[3] Sanofi Aventis Peru, Lima, Peru
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND37
引用
收藏
页码：S265 / S265
页数：1
相关论文
共 50 条
  • [21] A retrospective analysis in patients with relapsing-remitting multiple sclerosis
    Maeurer, Mathias
    Lang, Michael
    Elias, Wolfgang
    Ries, Stefan
    Reifschneider, Stefan
    Kaefferlein, Wolfgang
    Windhagen, Susanne
    Wensdoerfer, Colin
    Niemczyk, Gabriele
    Schikhnaier, Petra
    Schwab, Stefan
    MULTIPLE SCLEROSIS, 2008, 14 : S164 - S165
  • [22] Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis
    Aungsumart, Saharat
    Turongkaravee, Saowalak
    Youngkong, Sitaporn
    Apiwattanakul, Metha
    Thakkinstian, Ammarin
    Chaikledkaew, Usa
    BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
  • [23] BUDGET IMPACT ANALYSIS OF FINGOLIMOD IN RELAPSING REMITTING MULTIPLE SCLEROSIS
    Ruggeri, M.
    D'Ausilio, A.
    Lo Muto, R.
    Cottone, S.
    Ghezzi, A.
    Mecozzi, A.
    Sacchini, D.
    Mangone, M.
    VALUE IN HEALTH, 2014, 17 (07) : A393 - A393
  • [24] Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis
    Saharat Aungsumart
    Saowalak Turongkaravee
    Sitaporn Youngkong
    Metha Apiwattanakul
    Ammarin Thakkinstian
    Usa Chaikledkaew
    BMC Health Services Research, 23
  • [25] BUDGET IMPACT ANALYSIS OF FIRST-LINE TREATMENT FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
    Sanchez-de la Rosa, R.
    Sabater, E.
    Casado, M. A.
    VALUE IN HEALTH, 2011, 14 (07) : A319 - A319
  • [26] Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis
    Iovino, Aniello
    Aruta, Francesco
    Carotenuto, Antonio
    Manganelli, Fiore
    Iodice, Rosa
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 28 : 98 - 100
  • [27] Alemtuzumab and Thyroid Autoimmunity in Relapsing-Remitting Multiple Sclerosis Patients in CAMMS223
    Brinar, Vesna
    NEUROLOGY, 2011, 76 (09) : A246 - A246
  • [28] Efficacy of alemtuzumab in relapsing-remitting multiple sclerosis is independent of baseline status
    Coles, A. J.
    JOURNAL OF NEUROLOGY, 2007, 254 : 55 - 55
  • [29] Alopecia totalis following alemtuzumab treatment in relapsing-remitting multiple sclerosis
    Zimmermann, J.
    Buhl, T.
    Mueller, M.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 382 - 382
  • [30] Immunosuppresion following alemtuzumab in relapsing-remitting multiple sclerosis patients previously treated With fingolimod
    Maria Cabrera-Maqueda, Jose
    Fuentes Rumi, Luna
    Valero Lopez, Gabriel
    Alba Isasi, Teresa
    Hernandez-Clares, Rocio
    Carreon Guarnizo, Ester
    Jimenez Veiga, Judith
    Iniesta-Martinez, Francisca
    Leon-Hernandez, Aida
    Zamarro Parra, Joaquin
    Morales Ortiz, Ana
    Meca Lallana, Jose
    NEUROLOGY, 2019, 92 (15)
12345